STAT+: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market….
Category: Bristol-Myers Squibb
.jpg)
STAT+: Late-stage results set up Cytokinetics heart drug to compete with Bristol
Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last…
In a showy hearing, Bernie Sanders gets few answers about lower drug prices
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck…
STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves
SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two…
STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO…
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…